Company profile
REGENXBIO Inc.
RGNX · NASDAQ (Exact normalized legal-name match to SEC CIK 0001590877. Sources: https://clinicaltrials.gov/study/NCT03066258 ; https://data.sec.gov/submissions/CIK0001590877.json Sources: https://clinicaltrials.gov/study/NCT03066258 ; https://data.sec.gov/submissions/CIK0001590877.json Company created by asset-pipeline-v2/ownership-evidence-pass.)
Share price · RGNX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | VEGF-AGene therapy / editing | Age-Related Macular Degeneration | |
| Phase 3 | VEGF-AGene therapy / editing | Age-Related Macular Degeneration |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.